• 23 June, 2025

Lupin gets US FDA nod

December 29, 2014 | Monday | News | By BioSpectrum Bureau

Lupin gets US FDA nod

The company will now market generic version of ViiV Healthcare's Epivir Tablets in the US

The company will now market generic version of ViiV Healthcare's Epivir Tablets in the US

Lupin has announced that it has received the US Food and Drug Administration (US FDA) approval to market a generic version of ViiV Healthcare's Epivir Tablets, used in treating HIV infection.

According to the company, it has received final approval for its Lamivudine tablets in strengths of 150 mg and 300 mg.

Epivir tablets had annual US sales of $39.7 million as per IMS MAT September 2014 sales data.

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy